Ironwood Pharmaceuticals

IRWD · NASDAQ🇺🇸

Overview

Earnings Dividends Seasonality Metrics

NOV

10

Q3 2025

Reported

Reported earnings 3 months ago

Total Revenue

$122M

Previous year: $91.6M

U.S. LINZESS net sales

$315M

Previous year: $226M

+39.6%

LINZESS Rx demand growth

12%

LINZESS commercial margin

Previous year: $88.2M

+59.2%

Loading...

Ironwood Pharmaceuticals

Unlock previous datapoints

Upgrade

Ironwood Pharmaceuticals

Unlock previous datapoints

Upgrade

Ironwood Pharmaceuticals Revenue by Segment

Revenue by Segment

LINZESS collaboration Revenue

CapyFin.com

Royalties and other Revenue

CapyFin.com

Historical Earnings Impact

Analyze how earnings announcements historically affect stock price performance

Avg. Return Before/After Earnings

Loading earnings performance data...

Loading earnings reaction data...

Key Statistics

Market Cap

$796M

P/E Ratio

27.97

Sector

N/A

Industry

N/A

52-Week High

$5.37

52-Week Low

$0.536

U.S. LINZESS net sales

$315M

LINZESS Rx demand growth

12%

LINZESS commercial margin

76%

LINZESS capsules dispensed

60.5M

Products

Get in Touch

Resources

Ironwood Pharmaceuticals

Ironwood Pharmaceuticals

Ironwood Pharmaceuticals

Ironwood Pharmaceuticals Revenue by Segment

Revenue by Segment

LINZESS collaboration Revenue

Royalties and other Revenue

Historical Earnings Impact

Avg. Return Before/After Earnings

Key Statistics